These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8669868)

  • 1. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
    Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
    Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
    Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; De Nictolis M; Romanini C; Biagini G
    Gynecol Oncol; 1996 Apr; 61(1):83-9. PubMed ID: 8626123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
    Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
    Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
    J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
    Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
    Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.
    Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
    Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
    Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
    Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.